Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy.
The translation of fundamental science-based constructs to the preemptive identification and optimal management of individuals with or those at risk for thrombotic disorders of the cardiovascular system has taken a step closer to being realized with the development of molecular technologies that include nucleic acid aptamers and their complimentary oligonucleotide antidotes. Herein, we summarize our experience with factor IX and von Willebrand factor aptamers, and introduce the era of antithrombotic pharmacobiologic therapy.
Becker
R C
RC
Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA. becke021@mc.duke.edu
Oney
S
S
Becker
K C D
KC
Rusconi
C P
CP
Sullenger
B
B
D001779:Blood Coagulation Factors / Q000502:physiology; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D015912:Thrombolytic Therapy
D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents